Testing SHR-A1811 for HER2-positive breast cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This study tests a new drug, SHR-A1811, for women with HER2-positive breast cancer that has spread to the brain. The trial will see if the drug can shrink tumors in the brain and body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer is HER2-positive (a specific type that responds to targeted therapy) and has spread to the brain.
- You have not received a certain earlier drug called Enhertu (DS-8201a).
- You are willing to use effective birth control during the study and for 6 months after the last dose.
- You have adequate liver, kidney, and heart function (checked with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, SHR-A1811 and THPy, in people with HER2 positive advanced breast cancer that has spread to the brain. It is for those who have not received any previous treatment for advanced cancer.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a new drug called SHR-A1811, given either alone or with the hormone therapy letrozole, before surgery for women with early-stage breast cancer that is hormone receptor positive and HER2-low. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This trial tests a new drug (SHR-A1811) combined with radiation therapy for people with HER2-positive or HER2-low breast cancer that has spread to the brain. It aims to see if the combination can better control brain metastases.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.